Bronchiolitis Obliterans Syndrome (BOS) Recruiting Phase 1 Trials for Itacitinib (DB12154)

Also known as: Bronchiolitis Obliterans (BO) / Bronchiolitis Obliterans / Obliterative Bronchiolitis / Bronchiolitis Obliterans Syndrome / Obliterating fibrous bronchiolitis (disorder) / Bronchiolitis fibrosa obliterans (disorder) / Obliterative bronchiolitis (disorder)

IndicationStatusPhase
DBCOND0071683 (Bronchiolitis Obliterans Syndrome (BOS))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04239989Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell TransplantTreatment